Core C will provide centralized and curated molecular diagnostics services, cell banking and distribution functions. All three projects rely on precise and accurate definition of the deletion mutations in each of the dystrophinopathy patients under study. The recruitment of all human subjects will be through the existing Cooperative International Neuromuscular Research Group (CINRG), with an established Coordinating Center (at Children's National Medical Center), elected Executive Committee, and 24 clinical recruitment sites. The CINRG group has an ongoing federally funded natural history study of 348 Duchenne muscular dystrophy patients, and multiple ongoing additional natural history studies and clinical trials of Duchenne/Becker muscular dystrophy and limb-girdle muscular dystrophy patients. Dystrophinopathy patient samples will be received from two distinct IRB protocols. For Duchenne muscular dystrophy participants (out-of-frame mutations). Core C will originate a protocol for receipt of blood (DNA) and skin biopsies (Aim 1). The Core will establish fibroblast cultures, validate and refine the deletion mutations using arrays and nextgen sequencing, and then distribute cells to Project 2. In the second human subject protocol. Project 3 will originate the protocol for a Becker muscular dystrophy natural history study (In-frame mutations), and collect blood (DNA), skin biopsy, and optional muscle biopsy specimens from each participant in the clinical study. All participant samples will be received and banked by Core C. DNA samples from both Duchenne and Becker muscular dystrophy patients will be tested for validation and refinement of the deletion mutations/breakpoints. Skin biopsies will be cultured for fibroblasts and cell cultures sent to Projects 1 and 2 and banked. Muscle biopsies will be sent to Project 1. Innovation is through novel methods of Identification of deletion breakpoints, and application of nextgen sequencing methods (Pacific Biosciences, lllumina). Resource sharing will include entry of alt patient mutation data Into existing International databases (Leiden Muscular Dystrophy Pages;TREAT-NMD Registry). The Core will send fibroblast cultures to external Investigators upon request. The Core will also be available for application of Innovative molecular diagnostics technologies to external investigators on a collaborative basis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Specialized Center (P50)
Project #
5P50AR060836-04
Application #
8734219
Study Section
Special Emphasis Panel (ZAR1)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
4
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Children's Research Institute
Department
Type
DUNS #
City
Washington
State
DC
Country
United States
Zip Code
20010
Jain, Harsh V; Boehler, Jessica F; Nagaraju, Kanneboyina et al. (2018) Synthesis, Characterization, and Function of an RNA-Based Transfection Reagent. Curr Protoc Nucleic Acid Chem 72:4.81.1-4.81.29
Yu, Qing; Morales, Melissa; Li, Ning et al. (2018) Skeletal, cardiac, and respiratory muscle function and histopathology in the P448Lneo- mouse model of FKRP-deficient muscular dystrophy. Skelet Muscle 8:13
Jain, H V; Boehler, J F; Verthelyi, D et al. (2017) An amphipathic trans-acting phosphorothioate RNA element delivers an uncharged phosphorodiamidate morpholino sequence in mdx mouse myotubes. RSC Adv 7:42519-42528
Vila, Maria C; Rayavarapu, Sree; Hogarth, Marshall W et al. (2017) Mitochondria mediate cell membrane repair and contribute to Duchenne muscular dystrophy. Cell Death Differ 24:330-342
Echigoya, Yusuke; Lim, Kenji Rowel Q; Trieu, Nhu et al. (2017) Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy. Mol Ther 25:2561-2572
Defour, Aurelia; Medikayala, Sushma; Van der Meulen, Jack H et al. (2017) Annexin A2 links poor myofiber repair with inflammation and adipogenic replacement of the injured muscle. Hum Mol Genet 26:1979-1991
Benny Klimek, Margaret E; Sali, Arpana; Rayavarapu, Sree et al. (2016) Effect of the IL-1 Receptor Antagonist Kineret® on Disease Phenotype in mdx Mice. PLoS One 11:e0155944
Hathout, Yetrib; Seol, Haeri; Han, Meng Hsuan J et al. (2016) Clinical utility of serum biomarkers in Duchenne muscular dystrophy. Clin Proteomics 13:9
Coley, William D; Bogdanik, Laurent; Vila, Maria Candida et al. (2016) Effect of genetic background on the dystrophic phenotype in mdx mice. Hum Mol Genet 25:130-45
Hathout, Yetrib; Conklin, Laurie S; Seol, Haeri et al. (2016) Serum pharmacodynamic biomarkers for chronic corticosteroid treatment of children. Sci Rep 6:31727

Showing the most recent 10 out of 41 publications